Table of Contents
Pathology Research International
Volume 2011, Article ID 219309, 11 pages
Review Article

Impact of KRAS Mutations on Management of Colorectal Carcinoma

Department of Medicine, Section of Hematology/Oncology, Albert Einstein College of Medicine, Beth Israel Medical Center, Phillips Ambulatory Care Center, 10 Union Square East, Suite 4C, NY 10003, USA

Received 28 September 2010; Revised 2 January 2011; Accepted 10 January 2011

Academic Editor: Wade Samowitz

Copyright © 2011 Kevin M. Sullivan and Peter S. Kozuch. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [9 citations]

The following is the list of published articles that have cited the current article.

  • Albrecht Stenzinger, Moritz von Winterfeld, Anja Rabien, Arne Warth, Carsten Kamphues, Manfred Dietel, Wilko Weichert, Frederick Klauschen, and Daniel Wittschieber, “Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer,” Human Pathology, vol. 43, no. 8, pp. 1314–1321, 2012. View at Publisher · View at Google Scholar
  • George Poulogiannis, Feijun Luo, and Mark J. Arends, “RAS signalling in the colorectum in health and disease,” Cell Communication And Adhesion, vol. 19, no. 1, pp. 1–9, 2012. View at Publisher · View at Google Scholar
  • George Orphanides, Christine M. Chresta, Gael McWalter, Sara Davenport, Tim French, Garry Beran, Alison Pritchard, Susie Weston, Kerry Heathcote, Lodewyk F. A. Wessels, Andreas Schlicker, Denis Alferez Castro, and Sarah Runswick, “Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines,” Bmc Medical Genomics, vol. 5, 2012. View at Publisher · View at Google Scholar
  • Efat Azizi, Adam Kittai, and Peter Kozuch, “Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.,” Chemotherapy research and practice, vol. 2012, pp. 198197, 2012. View at Publisher · View at Google Scholar
  • Satya Dattatreya, “Metastatic colorectal cancer-prolonging overall survival with targeted therapies.,” South Asian journal of cancer, vol. 2, no. 3, pp. 179–85, 2013. View at Publisher · View at Google Scholar
  • Felix Gremse, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Lotfi Abou-Elkacem, Susanne Arns, and Gunnar Brix, “Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model,” Molecular Cancer Therapeutics, vol. 12, no. 7, pp. 1322–1331, 2013. View at Publisher · View at Google Scholar
  • Rosemary A Poku, Felix Amissah, Randolph Duverna, Byron J Aguilar, Gebre-Egziabher Kiros, and Nazarius S Lamango, “Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer.,” Ecancermedicalscience, vol. 8, pp. 459, 2014. View at Publisher · View at Google Scholar
  • Narendra Padhan, Torbjörn E. M. Nordling, Magnus Sundström, Peter Åkerud, Helgi Birgisson, Peter Nygren, Sven Nelander, and Lena Claesson-Welsh, “High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer,” BMC Cancer, vol. 16, no. 1, 2016. View at Publisher · View at Google Scholar
  • S T Guo, Y F Wang, L Jin, X D Zhang, C C Jiang, X Y Guo, J Wang, C Y Wang, R H Yang, F H Wang, X Y Li, H Hondermarck, and R F Thorne, “MicroRNA-645 is an oncogenic regulator in colon cancer.,” Oncogenesis, vol. 6, no. 5, 2017. View at Publisher · View at Google Scholar